Lung fibrosis & COVID mRNA gene injection? Seems so, I describe an Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Pfizer mRNA COVID-19 Vaccination as well as interstitial lung disease

by Paul Alexander

Once again, researchers draw conclusions that do not match the core findings of harms, they refuse to discuss the catastrophic subversion of the immune system of the vaccinated person e.g. cancer risk

Here researchers report on a case linked to the taking of the Pfizer shot, yet still say it is worth it. How? Where is the benefit-risk calculus for us to accept that conclusion?

The finding that a significant number of patients hospitalized for AE-IPF (adverse effects, idiopathic pulmonary fibrosis) have a close temporal relationship and link with COVID vaccination (mRNA platforms) indicates that the immune response induced by the gene injection vaccine may initiate and activate pathophysiological and pathobiological cascades of events that leads to adverse outcomes in susceptible patients.



‘Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by progressive scar tissue formation. An acute exacerbation of IPF (AE-IPF) is a clinically significant respiratory decompensation that accounts for a significant proportion of IPF-related morbidity and mortality.

AE-IPF can be idiopathic or associated with pulmonary embolism, infection, aspiration, surgery, and drug toxicity. In this novel case report, we describe a potential association between AE-IPF and BNT162b2 mRNA COVID-19 vaccination that was successfully treated with a short course of glucocorticoids. While our aim is to raise awareness for this yet-to-be-described adverse event, immunization against vaccine-preventable disease remains widely recommended in vulnerable patients with chronic lung disease such as IPF.’

Example 2:


‘A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio.

These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.’

Example 3:


Further reporting on the above (example 3) Sgalla research:

‘Researchers evaluated 26 patients with an IPF diagnosis who were hospitalized for respiratory worsening from January to December 2021. Acute exacerbations of IPF were defined as acute, clinically significant respiratory deteriorations characterized by bilateral ground-glass opacification/consolidation at chest imaging. Overall, 16 patients had their deterioration explained by progression of underlying fibrotic disease, pulmonary embolism, infection or fluid overload, and 10 patients had an acute IPF exacerbation diagnosis based on radiologic findings and exclusion of other respiratory worsening causes.

All patients received the Pfizer-BioNTech COVID-19 vaccination.

Forty percent of patients with acute IPF exacerbation (mean age, 71.5 years; 25% women) were referred to the ED for worsening dyspnea that occurred a few days after COVID-19 vaccination. Deterioration occurred after the first dose of the vaccine in one patient, after the second dose in another patient and after the third dose in the remaining two patients. The median time interval between the COVID-19 vaccination and symptom onset was 3.5 days among these patients, which suggest the vaccine as the likely cause of acute IPF exacerbation.

Among those who experienced respiratory worsening after their COVID-19 vaccination, three patients had a pattern of usual interstitial pneumonia at diagnosis.’

‘Our observations suggest that COVID-19 vaccination may act as a potential trigger of acute exacerbation IPF, warranting a close monitoring strategy of IPF patients after vaccination to early detect worsening of symptoms of oxygen desaturation, requiring immediate clinical referral,” the researchers wrote.’


Example 4:


‘We report two cases of COVID-19 mRNA vaccine-related interstitial lung disease (ILD). A 67-year-old man and a 70-year-old man with underlying ILD presented to our hospital with a few days of fever and respiratory symptoms after receiving the BNT162b2 vaccine.

Drug-related pneumonitis due to the COVID-19 mRNA vaccine was diagnosed. One case was diagnosed with lymphocytic alveolitis by bronchoalveolar lavage fluid and transbronchial lung cryobiopsy.

Both patients were successfully treated with corticosteroids, and they attended outpatient clinics thereafter. Although the safety and efficacy of COVID-19 vaccines have been established, further studies are needed to estimate long-term data and reports of rare adverse reactions. We present the clinical course of two cases, review previously published case reports on COVID-19 mRNA vaccine-related ILD and discuss the relevant findings.’